Is this pharma stock about to bounce back in 2021?

Is the demand for elective surgeries about to explode? Zaven Boyrazian analyses a pharma stock perfectly positioned to take advantage of the growing demand.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

The pandemic has created a challenging environment for pharma stocks like Advanced Medical Solutions (LSE:AMS).  Its performance in 2020 is best described as lacklustre, but not entirely unexpected.

The business is a developer and manufacturer of surgical and wound care products. These range from tissue adhesives to wound dressings sold under multiple globally recognised brands. With lockdowns keeping people at home, A&E visits have dropped by almost half. Furthermore, with hospitals overwhelmed by Covid-19 patients, many elective surgeries have been delayed by a similar rate.

Combined, this had led to a significant decline in product sales. But now that the vaccine rollout is underway, is the tide about to change? Is this pharma stock about to make a comeback in 2021? And should I consider adding it to my portfolio? 

A pioneer in wound care

AMS has been around since the early 1990s. It was initially a research and development firm. But skip forward a few decades and a couple acquisitions, and the pharma stock has become a leader within its market space.

The business can be broken up into two units. Unit one is called Surgical. It sells AMS branded products to medical centres – such as hospitals – directly or through third-party distributors. The second unit is called Woundcare. This division develops and supplies a wide range of products to its business partners, who subsequently use them to create their own branded products.

Both segments are responsible for generating a roughly even split of total revenue. However, the Surgical unit appears to be significantly more profitable, with an operating margin of 34% in 2019.

As previously stated, Covid-19 has had a major impact on this stock. While its manufacturing facilities remained in operation throughout 2020, general demand for the firm’s products fell sharply. As a result, forecast revenue for 2020 is expected to be around 20% lower than in 2019.

However, the catalyst behind this poor performance looks only temporary to me. And with Covid-19 slowly coming under control, I believe that demand can return and even grow in the latter part of 2021. But as always, there are plenty of challenges and risks ahead.

A fiercely competitive market

Wound care and surgical are highly competitive spaces. While regulators make it difficult for new entrants, the number of global competitors for the company continues to rise.

As such, the need to continually innovate and expand its intellectual property portfolio is exceptionally high. But this might begin straining the company’s financials.

Fortunately, there’s a large proportion of cash on the balance sheet that has proven vital to continue funding its R&D department throughout the pandemic. However, should the business make another acquisition, this cash balance may no longer be available to rely on if another similar event were to occur.

Is this pharma stock about to create explosive returns

Is the pharma stock on my buy list?

AMS looks perfectly positioned for a rebound in my eyes. Assuming that demand returns to pre-Covid levels later this year, the current stock price seems relatively low. The fierce competition will continue to be an ever-present threat, but the potential reward might just outweigh the risk.

Therefore I think the stock could be a fantastic opportunity for value investors, and perhaps even my portfolio as well.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian does not own shares in Advanced Medical Solutions. The Motley Fool UK has recommended Advanced Medical Solutions. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

How risky is switching from cash savings to a Stocks and Shares ISA?

The UK government is making moves to encourage cash savers to consider investing via Stocks and Shares ISAs. But what…

Read more »

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

4,985 shares of this FTSE dividend star pay an income equal to the State Pension!

Zaven Boyrazian calculates how many shares investors would have to buy to generate enough income to match the UK State…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

£500 buys me 407 shares in this 8.2%-yielding income stock!

Got a small lump sum? Zaven Boyrazian explores one underappreciated income stock offering an enormous yield that could be set…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Up 23% this year, is it too late to buy shares in this FTSE 100 compounder?

Having missed Diploma shares at £36 back in April, is a strong trading update with higher guidance a good enough…

Read more »

Businessman hand flipping wooden block cube from 2024 to 2025 on coins
Investing Articles

Does this ex-penny stock have the potential to almost double?

This under-the-radar mining stock has doubled in the last 12 months, lifting it out of penny stock territory. But could…

Read more »

A mature adult sitting by a fireplace in a living room at home. She is wearing a yellow cardigan and spectacles.
Investing Articles

£5k in savings? Here’s how that can unlock a £255 monthly second income

Ever wondered how to turn a lump sum of savings into a chunky second income? Zaven Boyrazian explains a simple…

Read more »

British pound data
Investing Articles

Get ready for a US stock market crash?

Experts are waving the red flag on the US stock market and economy, warning of an impending crash. Should investors…

Read more »

The words "what's your plan for retirement" written on chalkboard on pavement somewhere in London
Investing Articles

How I’m positioning my SIPP for the AI revolution

Artificial intelligence is likely to disrupt every industry. Edward Sheldon is hoping to capitalise on the growth of AI through…

Read more »